567 related articles for article (PubMed ID: 17149362)
41. TargetFinder: a software for antisense oligonucleotide target site selection based on MAST and secondary structures of target mRNA.
Bo X; Wang S
Bioinformatics; 2005 Apr; 21(8):1401-2. PubMed ID: 15598838
[TBL] [Abstract][Full Text] [Related]
42. Controlled delivery of antisense oligonucleotides: a brief review of current strategies.
Zhao X; Pan F; Holt CM; Lewis AL; Lu JR
Expert Opin Drug Deliv; 2009 Jul; 6(7):673-86. PubMed ID: 19552611
[TBL] [Abstract][Full Text] [Related]
43. Toxicology of antisense therapeutics.
Jason TL; Koropatnick J; Berg RW
Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
[TBL] [Abstract][Full Text] [Related]
44. Discovery and analysis of antisense oligonucleotide activity in cell culture.
Baker BF; Condon TP; Koller E; McKay RA; Siwkowski AM; Vickers TA; Monia BP
Methods; 2001 Feb; 23(2):191-8. PubMed ID: 11181038
[TBL] [Abstract][Full Text] [Related]
45. Suppression of survivin expression by short hairpin RNA induces apoptosis in human laryngeal carcinoma cells.
Chen XM; Luan XY; Lei DP; Ma XJ; Liu XX; Liu J; Pan XL
ORL J Otorhinolaryngol Relat Spec; 2008; 70(3):168-75. PubMed ID: 18391576
[TBL] [Abstract][Full Text] [Related]
46. Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma.
Chau GY; Lee AF; Tsay SH; Ke YR; Kao HL; Wong FH; Tsou AP; Chau YP
Histopathology; 2007 Aug; 51(2):204-18. PubMed ID: 17559540
[TBL] [Abstract][Full Text] [Related]
47. [Screening and their anti-tumor activity of antisense oligodeoxynucleotides targeting KDR mRNA in breast cancer MCF-7 cells].
Zheng SJ; Lin RX; Xia Y; Bo XC; Ren H; Zhong S; Wang SQ
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):248-52. PubMed ID: 16875620
[TBL] [Abstract][Full Text] [Related]
48. Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate.
Lima WF; Rose JB; Nichols JG; Wu H; Migawa MT; Wyrzykiewicz TK; Siwkowski AM; Crooke ST
Mol Pharmacol; 2007 Jan; 71(1):83-91. PubMed ID: 17028158
[TBL] [Abstract][Full Text] [Related]
49. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus.
Liang XH; Sun H; Nichols JG; Crooke ST
Mol Ther; 2017 Sep; 25(9):2075-2092. PubMed ID: 28663102
[TBL] [Abstract][Full Text] [Related]
50. Downregulation of human FGF8 activity by antisense constructs in murine fibroblastic and human prostatic carcinoma cell systems.
Rudra-Ganguly N; Zheng J; Hoang AT; Roy-Burman P
Oncogene; 1998 Mar; 16(11):1487-92. PubMed ID: 9525747
[TBL] [Abstract][Full Text] [Related]
51. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target.
Capalbo G; Rödel C; Stauber RH; Knauer SK; Bache M; Kappler M; Rödel F
Strahlenther Onkol; 2007 Nov; 183(11):593-9. PubMed ID: 17960333
[TBL] [Abstract][Full Text] [Related]
52. Effects of Survivin on cell proliferation and apoptosis in MG-63 cells in vitro.
Liang X; Da M; Zhuang Z; Wu W; Wu Z; Wu Y; Shen H
Cell Biol Int; 2009 Jan; 33(1):119-24. PubMed ID: 18996209
[TBL] [Abstract][Full Text] [Related]
53. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries.
Ho SP; Bao Y; Lesher T; Malhotra R; Ma LY; Fluharty SJ; Sakai RR
Nat Biotechnol; 1998 Jan; 16(1):59-63. PubMed ID: 9447595
[TBL] [Abstract][Full Text] [Related]
54. Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides. The most effective target sites are clustered in double-stranded regions of the predicted secondary structure for the mRNA.
Laptev AV; Lu Z; Colige A; Prockop DJ
Biochemistry; 1994 Sep; 33(36):11033-9. PubMed ID: 8086420
[TBL] [Abstract][Full Text] [Related]
55. 2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo.
Prakash TP; Johnston JF; Graham MJ; Condon TP; Manoharan M
Nucleic Acids Res; 2004; 32(2):828-33. PubMed ID: 14762210
[TBL] [Abstract][Full Text] [Related]
56. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
57. [Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice].
Zhang Y; Ma Y; Lu HP; Zhou XF; Xie Y; Gao JH; Liang CS
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(29):2073-6. PubMed ID: 19080439
[TBL] [Abstract][Full Text] [Related]
58. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.
Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T
Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281
[TBL] [Abstract][Full Text] [Related]
59. Directed RNase H Cleavage of Nascent Transcripts Causes Transcription Termination.
Lai F; Damle SS; Ling KK; Rigo F
Mol Cell; 2020 Mar; 77(5):1032-1043.e4. PubMed ID: 31924447
[TBL] [Abstract][Full Text] [Related]
60. In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells.
Salvi A; Arici B; Portolani N; Giulini SM; De Petro G; Barlati S
Int J Oncol; 2007 Aug; 31(2):451-60. PubMed ID: 17611703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
